Aldeyra Therapeutics (ALDX) said Thursday it has resubmitted a new drug application to the US Food and Drug Administration for topical ocular reproxalap, which is being developed as a treatment for signs and symptoms of dry eye disease.

Included in the resubmission were previously disclosed results from a completed trial requested by the FDA following a review of the prior NDA, the company said.

Price: 5.28, Change: -0.02, Percent Change: -0.38